Venus Remedies

VENUSREM · NSE

— · —

₹1,710.6

Closing price — 29 Sept 2026

Market cap ₹2,286 Cr · EPS ₹84.68

Valuation

Blended fair value using DCF and peer comparison methods.

See if Venus Remedies is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Venus Remedies VENUSREM · you	₹2,154 Cr	19.0×	4.4×	—	22.9%	0.1%	—
Sector median	—	32.9×	4.7×	20.6×	15.6%	13.7%	16.7%
Eris Lifesciences ERIS	₹19,020 Cr	30.2×	4.8×	18.1×	15.9%	19.8%	22.9%
Onesource Specialty Pharma ONESOURCE	₹18,447 Cr	—	3.4×	64.6×	-1.3%	-5.2%	232.4%
AstraZeneca Pharma India Limited ASTRAZEN	₹17,766 Cr	94.7×	20.4×	67.4×	21.5%	8.2%	31.4%
Alivus Life Sciences Limited ALIVUS	₹16,540 Cr	29.9×	5.1×	20.4×	16.9%	22.1%	5.7%
NATCO Pharma NATCOPHARM	₹15,503 Cr	11.0×	1.7×	10.9×	15.4%	34.8%	14.6%
Jubilant Pharmova JUBLPHARMA	₹15,442 Cr	38.2×	2.1×	15.3×	5.6%	4.8%	9.6%
Marksans Pharma Limited MARKSANS	₹13,495 Cr	32.9×	4.5×	20.7×	13.8%	14.2%	16.8%
CORONA Remedies Limited CORONA	₹12,727 Cr	64.4×	16.0×	46.6×	24.8%	13.2%	16.6%

Peer comparison verdict

Venus looks attractively valued — trading at a discount to sector peers on P/E (20.2× vs sector median 32.9×) while delivering above-average returns on equity (22.9% vs 15.6%).

Business quality

Valuation

P/E ratio

20.2×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

22.9%

ROCE

—

ROA

—

Growth

Revenue CAGR (3yr)

—

EPS CAGR (3yr)

—

Efficiency

Asset turnover

—

FCF yield

—

Dividend yield

—

Liquidity & Solvency

Debt / Equity

—

Debt / EBITDA

—

Interest coverage

—

Current ratio

—

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Income statement data is unavailable for this company.

Cash flow

Where cash comes from and where it goes.

Cash flow data is not yet available for this company.

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

Balance sheet data is not yet available for this company.

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

Shareholding data is not yet available for this company.